# US 5,858,329 A · MRI diagnostic procedures using tripodal pyridinyl metal complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,858,329 A
- Document ID: US5858329A
- Status: Granted
- Kind: A
- Application number: 08/916,126
- Filed: 1997-08-21
- Granted: 1999-01-12
- Earliest claimed: 1997-08-21
- Assignees: Hoechst Celanese Corporation
- Inventors: Wei-Jen Peng; Humberto Ramos, Jr.
- Web page: https://patentgrep.com/patent/US5858329A

## CPC

- C07D 213/70: Sulfur atoms
- A61K 49/06: Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- C07D 213/71: to which a second hetero atom is attached
- C07D 213/80: in position 3
- C07F 9/59: Hydrogenated pyridine rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

A method of performing an NMR diagnostic procedure in a patient in need of the same comprising administering to the patient an effective amount of an NMR diagnostic medium and then exposing the patient to an NMR measurement step to which the diagnostic medium is responsive thereby imaging at least a portion of the patient's body, wherein the diagnostic medium comprises a composition of matter which contains a compound which has the structural formula: ##STR1## wherein R, R.sub.1 -R.sub.10 and M are defined herein.

## Claims

### Claim 1

A process of performing an MR imaging diagnostic procedure in a patient in need of the same comprising administering to the patient an effective amount of an MR imaging diagnostic medium and then exposing the patient to an MR imaging measurement step to which the diagnostic medium is responsive thereby imaging at least a portion of the patient's body, wherein the diagnostic medium comprises a composition of matter which contains a compound which has the structural formula: ##STR10## wherein: M is a suitable metal ion,
R.sub.1 is S, S(O).sub.n where n is 1
R.sub.2 -R.sub.10 are each independently selected from the group consisting of
(a) R
(b) OR
(c) N(R).sub.2
(d) NHC(O)R
(e) COO.sup.- M'
(f) C(O)N(R).sub.2, and
(g) SO.sub.3.sup.- M'
wherein R is selected from the group consisting of
(I) H
(ii) C.sub.1 -C.sub.20 alkyl
(iii) hydroxyalkyl (C.sub.1 -C.sub.30)
(iv) CH.sub.2 CH(OH)CH.sub.2 (O CH.sub.2 CH(OH)CH.sub.2).sub.n OH (n=0-10)
(v) CH.sub.2 CH.sub.2 (O CH.sub.2 CH.sub.2).sub.n OH (n=0-10)
(vi) ribose
(vii) glucose
(viii) peptide or polypeptide, and
(ix) PO.sub.3.sup.2- 2M'
and M' is Na.sup.+ or meglumine.

### Claim 2 (depends on 1)

The process as set forth in claim 1 wherein M is a metal ion of the lanthanide series having an atomic number of 57-71 or a transition metal of an atomic number of 21-29, 42 or 44.

### Claim 3 (depends on 1)

The process as set forth in claim 1 wherein at least one of R.sub.2 -R.sub.10 is hydrogen.

### Claim 4 (depends on 1)

The process as set forth in claim 1 wherein at least one of R.sub.2 -R.sub.10 is CH.sub.3.

### Claim 5 (depends on 1)

The process as set forth in claim 1 wherein at least one of R.sub.2 -R.sub.10 is OCH.sub.3.

### Claim 6 (depends on 1)

The process as set forth in claim 1 wherein at least one of R.sub.2 -R.sub.10 is NH.sub.2.

### Claim 7 (depends on 1)

The process as set forth in claim 1 wherein at least one of R.sub.2 -R.sub.10 is COONa.

### Claim 8 (depends on 1)

The process as set forth in claim 1 wherein R is hydrogen.

### Claim 9 (depends on 1)

The process as set forth in claim 1 wherein R is PO.sub.3 Na.sub.2.

### Claim 10 (depends on 1)

The process as set forth in claim 1 wherein R is peptide.

### Claim 11 (depends on 1)

The process as set forth in claim 1 wherein R is glucose.

### Claim 12 (depends on 1)

The process as set forth in claim 1 wherein R is C.sub.2 H.sub.5.

### Claim 13 (depends on 1)

The process as set forth in claim 1 wherein M is selected from the group consisting of chromium (III), manganese (II), iron (III), iron (II), cobalt (II), nickel (II), copper (II), praseodymium (III), neodymium (III), samarium (III), ytterbium (III), gadolinium (III), terbium (III), dysprosium (III), holmium (III), erbium (III), lanthanium (III), gold (III), lead (II), bismuth (III), lutetium (III), and europium (III).

### Claim 14 (depends on 1)

The process as set forth in claim 1 wherein M is gadolinium (III).

### Claim 15 (depends on 1)

The process as set forth in claim 1 wherein M is lutetium (III).

### Claim 16 (depends on 1)

The process as set forth in claim 1 wherein R.sub.1 is S.

### Claim 17 (depends on 1)

The process as set forth in claim 1 wherein R.sub.1 is SO.

### Claim 18 (depends on 1)

The process as set forth in claim 1 wherein the composition has the formula ##STR11## wherein n is 0 or 1.

### Claim 19 (depends on 1)

The process as set forth in claim 1 wherein the composition has the formula ##STR12## wherein: R.sub.1 is S or SO.
M is a metal ion of the lanthanide series having an atomic number 57-71
or a transition metal of an atomic number 21-29, 42 or 44.

### Claim 20 (depends on 19)

The process as set forth in claim 19 wherein M is gadolinium or lutetium.
